Form 4: Castle Biosciences Director Receives RSU Grant

Director Daniel Bradbury was granted 11,766 restricted stock units by Castle Biosciences, Inc. on May 28, 2026.

Summary

• Director Daniel Bradbury received a grant of 11,766 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of common stock.
• The grant was issued on May 28, 2026, with a zero-dollar exercise price.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon vesting.

Risks

• Vesting is subject to time-based conditions, specifically the earlier of the one-year anniversary or the next annual meeting.

Future Outlook

The RSUs are scheduled to vest in full on May 28, 2027, or the day preceding the next annual meeting of stockholders, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant of RSUs to directors is consistent with standard compensation practices for mid-cap biotechnology firms.
• The one-year vesting schedule aligns with typical industry benchmarks for director equity retention.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon the eventual conversion of RSUs to common stock.

Next Steps

• Vesting of the 11,766 RSUs on or before May 28, 2027.

Key Dates

Keywords

Castle Biosciences, CSTL, Form 4, Insider Transaction, Restricted Stock Units, Director Compensation